spacer
home > pmps > spring 2018 > traceable and transparent
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Traceable and Transparent

Theft and counterfeiting are two of the greatest issues threatening the pharmaceutical industry today, with claims that dangerous counterfeit drugs represent 10-30% of drugs available in developing countries, according to the WHO (1). Further research also estimates the cost of pharmaceutical theft to shippers and transporters alone at $30 billion a year, with an average of $4 million per loss. A deficit clearly needs to be resolved.

The supply chain of the average pharmaceutical product, from creation to delivery, is also continuing to expand geographically, as well as the number of companies involved in the chain itself. Pharma companies are relying on more and more partners to enable each stage of production and delivery to be as effective as possible and cater to new demands in the market, which, in turn, is increasing the complexity of the supply chain. A variety of additional forces are creating further complexities and will require companies reassess their strategies moving forward (2).

More diverse product types and therapies with shorter lifecycles mean the storage and delivery of certain drugs have also been transformed. New methods have been integrated for assessing, approving, and monitoring medicines, which is impacting how transparent each company has to be in terms of the supply chain. Finally, greater public scrutiny in the sector as well as tougher environmental controls and regulations are affecting the manner in which companies bring products to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julie Hurley, Global Director for Enterprise Solutions at Unisys, has an extensive pharma and life sciences background, with almost 20 years’ consulting to major pharma, biotechnology, and devices organisations in areas of strategic planning, industry best practice and implementation planning. She holds a patent, Genomic Sequencing for Clinical Trials, and has published several white papers, advertorials, and points of view.
spacer
Julie Hurley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 
Industry Events

10th Annual NGS & Clinical Diagnostics Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 10thAnnual NGS & Clinical Diagnostics Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement